CATAPULT GROUP INTERNATIONAL LIMITED (CAT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CAT - CATAPULT GROUP INTERNATIONAL LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Technology Hardware & Equipment
Debt/EBITDA: 2.06
Index: ALL-ORDS | ALL-TECH

Catapult Group develops and sells wearable sensors to monitor and analyse athletic performance, including fitness and skill levels, injury risks and rehabilitation assistance. It listed on the ASX in 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.38

20 Dec
2024

0.000

OPEN

$3.41

0.000

HIGH

$3.45

423,751

LOW

$3.36

TARGET
$4.00 18.3% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CAT: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) - 7.7 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192021202220232024
EPS Basic xxxxxxxxxxxxxxx-10.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx152.1 M
Book Value Per Share xxxxxxxxxxxxxxx48.3
Net Operating Cash Flow xxxxxxxxxxxxxxx45.4 M
Net Profit Margin xxxxxxxxxxxxxxx-16.68 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-20.36 %
Return on Invested Capital xxxxxxxxxxxxxxx-16.77 %
Return on Assets xxxxxxxxxxxxxxx-10.23 %
Return on Equity xxxxxxxxxxxxxxx-20.36 %
Return on Total Capital xxxxxxxxxxxxxxx-15.10 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx29.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx27 M
Total Debt xxxxxxxxxxxxxxx28 M
Goodwill - Gross xxxxxxxxxxxxxxx79 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx18 M
Price To Book Value xxxxxxxxxxxxxxx3.21

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192021202220232024
Capex xxxxxxxxxxxxxxx41.1 M
Capex % of Sales xxxxxxxxxxxxxxx27.05 %
Cost of Goods Sold xxxxxxxxxxxxxxx148 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx27 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgan Stanley

xx/xx/xxxx

-1

xx xxxxxx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

29/11/2024

1

Buy

$4.00

18.34%

Given the ongoing rally in the ASX Technology sector and rising multiples for similar companies, Bell Potter raises its valuation multiple for Catapult International.

The terminal growth assumption is also increased to 5% from 4% to be consistent with other SaaS companies the broker covers like WiseTech Global ((WTC)) and TechnologyOne ((TNE)).

In common with these companies, Catapult has a large total addressable market (TAM) and a strong competitive position in its market, explain the analysts.

The target rises to $4.00 from $3.30. Buy.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -7.71 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.78 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

19/11/2024

1

Buy

$3.50

3.55%

Canaccord Genuity observes Catapult International's 1H25 results outperformed expectations, with annualised contract value up 20% to US$97m and revenue rising 19% to US$58m, driven by subscription growth and efficient cost management.

EBITDA increased 68% to US$14m, with free cash flow turning positive at US$4m.

Performance and Health recorded 23% growth, while Tactics and Coaching rose 20%. The company's focus on wearables and video products offers a US$75m upside in annual contract values over the next three to five years, the broker highlights

Price target lifts to $3.50 from $2.50, reflecting a strong outlook. Buy rating unchanged.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -5.90 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.60 cents.
Access Extra Coverage Research History >

CAT STOCK CHART

FNArena News on CAT

1
November In Review: Valuation Concern Trumped

Dec 04 2024 - Australia
2
Australian Broker Call *Extra* Edition – Nov 19, 2024

Nov 19 2024 - Daily Market Reports
3
FNArena Corporate Results Monitor – 15-11-2024

Nov 15 2024 - Australia
4
Weekly Ratings, Targets, Forecast Changes – 18-10-24

Oct 21 2024 - Weekly Reports
5
Rudi’s View: Growth Is Not A Dirty Word

Sep 25 2024 - Rudi's View

Latest Medical Equipment & Devices News

1
Diagnostic Imaging Radiates Opportunity

Dec 18 2024 - Small Caps
2
ResMed’s Bounce-Back Complete

Oct 29 2024 - Australia
3
Dr Boreham’s Crucible: Pro Medicus

Sep 04 2024 - Australia
4
Pro Medicus: Don’t Stop Me Now

Aug 20 2024 - Technicals
5
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
6
ResMed Silences The Doubters

Apr 29 2024 - Australia
7
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
8
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
9
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
10
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View